|YM BioSciences Announces Preclinical Results For JAK1/JAK2 Inhibitor CYT387 In Multiple Myeloma. Emergent Lowers FY 2011 Guidance; Issues Q3 2011 Revenue Guidance.|
|By Staff and Wire Reports|
|Thursday, 04 August 2011 18:00|
YM BioSciences Inc. (AMEX:YMI), announced preclinical results for JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance online edition of Leukemia on July 26, 2011.
The results demonstrate that CYT387 can inhibit MM cellular proliferation in a time- and dose-dependent manner and induce apoptosis (cell death) in human myeloma cell lines (HMCL).
When used in combination with the conventional anti-MM therapies melphalan and bortezomib, CYT387 synergized in killing HMCL and primary MM tumor cells. Pre-clinical evaluation of CYT387 has demonstrated that this orally bioavailable JAK inhibitor has promising anti-myeloma effects.
Emergent BioSolutions Inc. (NYSE:EBS), revised fiscal 2011 guidance and expects total revenues of $270 to $290 million and net income of $15 to $25 million. The reduction of fiscal 2011 expected total revenue is primarily driven by lower than expected fermentation yields during the six month period of 2011, which, in turn, is expected to result in an annual output this year of approximately 7 million doses.
For the third quarter of 2011, the Company expects total revenues of $50-$60 million. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue $327 million and net profit of $41 million for fiscal 2011; revenues of $118 million for the third quarter of 2011.
Amarantus BioSciences (OTCBB: AMBS), a biotechnology company developing a first-in-class anti-apoptosis therapeutic protein known as MANF, and Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com), a biotechnology company developing a buccal insulin spray technology known as Generex Oral-lyn™, currently in a Phase III trial, today are making public the details of their intended third joint diabetes research collaboration.
Biodel Inc. (Nasdaq:BIOD) today reported financial results for the third quarter ended June 30, 2011.
Blue Sphere Corp. (OTCBB: BLSP) (the "Company" or "Blue Sphere"), announces today that it has signed in July an agreement with Beijing Clinci Energy and Environment Technology Co. Ltd., an experienced Chinese company ("Clinci") with a proven technology to convert biomass to energy, to jointly implement 14 animal waste-to-energy projects in China.
Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the quarter ended June 30, 2011.
Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and Webcast on Friday, August 12 at 9:30 a.m. EDT to discuss the Company's second quarter results.
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease, today announced that a conference call will be held on Monday, August 8, 2011 at 8:30 a.m. EDT to discuss results for the second quarter ended June 30, 2011 and a business outlook for the remainder of 2011. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.
Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will release its second quarter 2011 financial results on Monday, August 8, 2011 after the financial markets close.
Lightwave Logic, Inc. (OTC Bulletin Board:LWLG), a technology company focused on the development of a Next Generation Non Linear Optical Polymer Materials Platform for applications in high speed fiber-optic data communications and optical computing, announced today that it has entered into an agreement with FiberLogix International Ltd. of Watford, UK to begin the development and testing of proprietary fiber optic medical diagnostic devices incorporating Lightwave Logic's advanced non-linear optical polymers.
Nektar Therapeutics (Nasdaq:NKTR) today reported its financial results for the second quarter ended June 30, 2011.
OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) today provided an update on current events and activities and announced its second quarter financial results.
Palatin Technologies, Inc. (NYSE Amex:PTN) confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
PROLOR Biotech, Inc. (NYSE Amex:PBTH) today reported positive results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults.
Vermillion, Inc. (NASDAQ:VRML), a molecular diagnostics company, today reported financial results for the second quarter ended June 30, 2011.
YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance online edition of Leukemia on July 26, 2011.